Feng Shi

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 2

Top Topics

Prognostic Factors

Placebo Controlled

Magnetic Resonance

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Yan-Song Lin, Shu-Kui Qin, Hui Yang, Feng Shi, Aimin Yang, Xingmin Han, Bin Liu, Zhiyong Li, Qinghai Ji, Lijun Tang, Zhiyong Deng, Yong Ding, Wei Fu, Xianhe Xie, Linfa Li, Xiaohui He, Zhongwei Lv, Qingjie Ma, Zan Shen, Zhuming Guo, Zhendong Chen, Yali Cui, Jian Tan, Zairong Gao, Shanghua Jing, Keyi Lu, Xianyang Luo, Yuan Zhang, Yong Fang, Zhendong Li, Yizhuang Cheng, Shangtong Lei, Sha Luan, Guang Chen, Guihua Wang, Liqing Wu, Lingling Liu
Multicenter randomized double-blind phase III trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Yihebali Chi, Xiangqian Zheng, Yuan Zhang, Feng Shi, Ying Cheng, Zhuming Guo, Ming-Hua Ge, Jianwu Qin, Jiewu Zhang, Zhendong Li, Xiaohong Zhou, Rui Huang, Xiao-Hong Chen, Hui Liu, Ruochuan Cheng, Zhengang Xu, Dapeng Li, Pingzhang Tang, Ming Gao
Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase Ⅱ Trial. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)